ADC Therapeutics (ADCT) Operating Leases (2019 - 2026)
ADC Therapeutics (ADCT) posted Operating Leases of $991000.0 for Q1 2026, down 4.16% sequentially from $1.0 million in Q4 2025, and down 87.47% YoY from $7.9 million in Q1 2025.
ADC Therapeutics (ADCT) Operating Leases (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Operating Leases for 8 years, with the latest figure at $991000.0 in Q1 2026.
- Quarterly Operating Leases fell 87.47% year-over-year to $991000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $991000.0 (down 87.47% YoY) and the FY2025 annual result came in at $1.0 million, down 87.07% from the prior year.
- Operating Leases declined to $991000.0 in Q1 2026 per ADCT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $12.4 million in Q1 2023 and troughed at $991000.0 in Q1 2026.
- A 5-year average of $7.4 million and a median of $7.9 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2026: Operating Leases soared 79.65% in 2023, then plunged 87.47% in 2026.
- Over 5 years, Operating Leases stood at $6.6 million in 2022, then surged by 55.09% to $10.2 million in 2023, then declined by 21.46% to $8.0 million in 2024, then slumped by 87.07% to $1.0 million in 2025, then slipped by 4.16% to $991000.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $991000.0, $1.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 946,000.00 |
| Mar 31, 2026 | 991,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 7.91 Mn |
| Dec 31, 2024 | 8.00 Mn |
| Sep 30, 2024 | 8.88 Mn |
| Jun 30, 2024 | 9.31 Mn |
| Mar 31, 2024 | 9.66 Mn |
| Dec 31, 2023 | 10.18 Mn |
| Sep 30, 2023 | 11.49 Mn |
| Jun 30, 2023 | 12.39 Mn |
| Mar 31, 2023 | 12.40 Mn |
| Dec 31, 2022 | 6.56 Mn |
| Sep 30, 2022 | 7.46 Mn |
| Jun 30, 2022 | 6.90 Mn |
| Mar 31, 2022 | 7.60 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Sep 30, 2021 | 8.20 Mn |